Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.76 |
| ▸ | SNCA | P37840 | 12/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | CDK4 | P11802 | 1/20 | 0.65 |
| ▸ | CCND1 | P24385 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936412 | 0.94 | SNCA (0.84) | TRPV1SNCAMAPTPOLBKMT2A | |
| SCHEMBL9936100 | 0.92 | SNCA (0.79) | TRPV1SNCAMAPTPOLBKMT2A | |
| SCHEMBL9935439 | 0.91 | SNCA (0.85) | TRPV1SNCAMAPTPOLBKMT2A | |
| SCHEMBL9935377 | 0.89 | MAPT (0.80) | SNCAMAPT | |
| SCHEMBL15313141 | 0.89 | SNCA (0.88) | TRPV1SNCAPOLBKMT2AACHE | |
| SCHEMBL9936157 | 0.88 | SNCA (0.76) | SNCAMAPTCDK4CCND1 | |
| SCHEMBL9936475 | 0.87 | SNCA (0.80) | TRPV1SNCAMAPTKMT2ACDK4 | |
| SCHEMBL9936393 | 0.87 | MAPT (0.76) | SNCAMAPT | |
| SCHEMBL9936354 | 0.86 | TRPV1 (1.00) | TRPV1POLBKMT2AACHECDK4 | |
| SCHEMBL9936373 | 0.86 | SNCA (0.76) | SNCAMAPTCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651887-B1 | N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9284271-B2 | Compounds for the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-03-15 | — | — | US | disclosed |
| US-9284271-B2 | Compounds for the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-03-15 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| EP-2651887-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080220-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | TRPV1 2472/4885SNCA 1/4885MAPT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.